Alector Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
18.3%projected annual EPS growth
Analyst Coverage
5analysts covering
FY EPS (est.)
-$0.88next fiscal year
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Investments Quarterly206.5MTarget: Sufficient to fund operations at least through 2027
Quarterly Collaboration Revenue Quarterly1M
Quarterly Net Loss Quarterly-22.9M
Watch Items
- IND Submission for AL037/AL137 (ABC-enabled anti-A̢ antibody)Trigger: Targeted for Q1 2027Action: Initiate Phase 1 single ascending dose study in healthy volunteers and transition to multiple ascending dose study in early Alzheimer's disease patients.
- IND Submission for AL050 (ABC-enabled GCase enzyme replacement therapy)Trigger: Targeted for 2027Action: Advance preclinical IND-enabling work to support clinical entry for Parkinson's disease.
- Preclinical siRNA Platform Advancements (AL164, ADP062, ADP065)Trigger: Lead selection and IND-enabling studiesAction: Monitor progress of modified tau-targeting siRNA (AL164) and lead selection for alpha-synuclein and NLRP3 siRNA programs.
Research as of 20 Jun 2026